Matthew Alan Sharp

US Patent:

7425639, Sep 16, 2008

Filed:

Dec 17, 2001

Appl. No.:

10/470907

Inventors:

Jason William Beames Cooke - Stevenage, GB
Bobby Neal Glover - Durham NC, US
Ronnie Maxwell Lawrence - Stevenage, GB
Matthew Jude Sharp - Durham NC, US
Maria Fumiko Tymoschenko - Durham NC, US

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

C07D 401/00
C07D 233/00

US Classification:

5483471, 5483151, 5483154, 5483481, 5483491, 5462751

Abstract:

An improved process for preparing arylethanoldiamines is described. Compounds of this type are known to be useful as agonists at a typical beta-adrenoceptors (also known as beta-3-adrenoceptors).

US Patent:

7709677, May 4, 2010

Filed:

Aug 12, 2008

Appl. No.:

12/189941

Inventors:

Jason William Beames Cooke - Stevenage, GB
Bobby Neal Glover - Durham NC, US
Ronnie Maxwell Lawrence - Stevenage, GB
Matthew Jude Sharp - Durham NC, US
Maria Fumiko Tymoschenko - Durham NC, US

Assignee:

GlaxoSmithKline LLC - Philadelphia PA

International Classification:

C07C 229/00
C07C 211/00

US Classification:

560 19, 564336

Abstract:

An improved process for preparing arylethanoldiamines is described. Compounds of this type are known to be useful as agonists at atypical beta-adrenoceptors (also known as beta-3-adrenoceptors).

US Patent:

62945807, Sep 25, 2001

Filed:

Aug 25, 1998

Appl. No.:

9/125750

Inventors:

Timothy Mark Willson - Durham NC
Robert Anthony Mook - Chapel Hill NC
Istvan Kaldor - Durham NC
Brad Richard Henke - Cary NC
David Norman Deaton - Cary NC
Jon Loren Collins - Durham NC
Jeffrey Edmond Cobb - Chapel Hill NC
Marcus Brackeen - Durham NC
Matthew Jude Sharp - Apex NC
John Mark O'Callaghan - Kent, GB
Greg Alan Erickson - Cary NC
Grady Evan Boswell - Cary NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

A61K 3119
A61K 31135
C07C22100
C07D33332
C07D21172

US Classification:

514570

Abstract:

A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C. sub. 1-6 alkyl, C. sub. 1-3 alkoxy, C. sub. 1-3 fluoroalkoxy, nitrile, or --NR. sup. 7 R. sup. 8 where R. sup. 7 and R. sup. 8 are independently hydrogen or C. sub. 1-3 alkyl; (ii) a 5- or 6-membered hetrocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C. sub. 1-6 alkylene; (v) --MC. sub. 1-6 alkylene or C. sub.

US Patent:

62488910, Jun 19, 2001

Filed:

Jan 19, 2000

Appl. No.:

9/403158

Inventors:

Matthew Jude Sharp - Apex NC
Catherine J. Mader - Durham NC
Calum Strachan - Montrose, GB

Assignee:

Glaxo Wellcome, Inc. - Research Triangle Park NC

International Classification:

C07D21906

US Classification:

546103

Abstract:

Synthesis of the MDRI of formula (I) from intermediates of acridone acid of formula (II) and aminophenethyl isoquinoline of formula (III), via steps including coupling and conversion to yield the MDRI of formula (I).

US Patent:

55413226, Jul 30, 1996

Filed:

Oct 14, 1994

Appl. No.:

8/323404

Inventors:

Francis G. Fang - Durham NC
Matthew J. Sharp - Apex NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

C07D22118

US Classification:

546 42

Abstract:

A process of providing novel compounds of Formula (I), that are useful as 6-azaandrostenone testosterone 5-alpha-reductase inhibitors, from commercially available compounds of Formula (II) ##STR1## wherein the substituents are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof.

US Patent:

20220249496, Aug 11, 2022

Filed:

Dec 17, 2021

Appl. No.:

17/554316

Inventors:

- Pittsboro NC, US
Matthew J. SHARP - Apex NC, US

International Classification:

A61K 31/522
A61K 9/00
A61K 9/06
A61K 47/10

Abstract:

Provided herein are gel formulations of acyclovir with a low concentration of acyclovir, which can be used, for example, for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The gel formulation can be an aqueous gel formulation, an emulsified gel formulation, or a non-aqueous gel formulation.

US Patent:

20200390773, Dec 17, 2020

Filed:

Jun 12, 2020

Appl. No.:

16/899952

Inventors:

- Pittsboro NC, US
Matthew J. Sharp - Apex NC, US

International Classification:

A61K 31/522
A61K 9/06
A61K 9/00
A61K 47/10

Abstract:

Provided herein are gel formulations of acyclovir with a low concentration of acyclovir, which can be used, for example, for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The gel formulation can be an aqueous gel formulation, an emulsified gel formulation, or a non-aqueous gel formulation.